Stambomycin and derivatives, their production and their uses as drugs
The present invention relates to Stambomycin compounds, their derivatives and their pharmaceutically acceptable salt thereof.
1. A compound
selected from the group consisting of:
said compound being in the form of a racemate, any one of its enantiomers or diastereomers, or any one of the tautomers of said racemates, enantiomers and diastereomers, or a respective pharmaceutically acceptable salt thereof.
2. A process for producing the compound of claim 1 , comprising:
activating a silenced large type I polyketide synthase (PKS) gene cluster of a microorganism belonging to the family of Streptomycetaceae,
either by artificially over-expressing a transcriptional activator in said microorganism, wherein said transcriptional activator comprises the amino acid sequence SEQ ID NO: 1,
or by culturing said microorganism in R2 medium allowing the expression of said transcriptional activator at a level sufficient to activate the expression of said PKS genes,
said microorganism being Streptomyces ambofaciens deposited at the American Type Culture Collection (ATCC) under the number ATCC 23877; and
isolating said compound.
3. An isolated microorganism producing the compound of claim 1 , said microorganism being deposited at the Collection Nationale de Culture des Microorganismes (CNCM; Institut Pasteur), under the number CNCM-I-4175, said microorganism being transformed to permanently express a transcriptional activator consisting of the amino acid sequence SEQ ID NO: 1.
4. A pharmaceutical composition, comprising at least one compound according to claim 1 as active ingredient, in association with a pharmaceutically acceptable vehicle.
5. A method for treating pathologies associated with a bacterial infection, comprising administering to an individual in need thereof an effective amount of at least one compound as defined in claim 1 .
6. A method for treating cancer, comprising administering to an individual in need thereof an effective amount of at least one compound as defined in claim 1 .
7. The process according to claim 2 , wherein said PKS gene cluster is located about 500 Kbases from the end of the right arm of the chromosome of said microorganism.
8. The pharmaceutical composition according to claim 4 , further comprising at least one additional antitumor compound or at least one additional antibacterial compound.
9. The method according to claim 5 , wherein the effective amount of the at least one compound is from about 2 to 5 g/day.
10. The method according to claim 5 , wherein the effective amount of the at least one compound is from about 50-100 mg/kg/day.
11. The method according to claim 5 , wherein the pathology associated with a bacterial infection is sepsis, septicemia, nosocomial disease, Staphylococcus aureus infection, Lyme disease, cellulitis, osteomylitis, syphilis, bacterial meningitis or plague.
12. The method according to claim 5 , wherein the cancer is lung cancer, breast cancer, prostate cancer, bladder cancer, intestinal cancer, colon cancer, skin cancer, brain cancer, leukemia or lymphoma.